Health CanadaGeneral Alert
Janus Kinase Inhibitors and the Risk of Major Adverse Cardiovascular Events, Thr...
Published: October 31, 2022Recall ID: 72122Category: generalCountry: Canada
Reason for Recall / Hazard
New safety information - Product safety
Product Description & Identification
Janus Kinase Inhibitors and the Risk of Major Adverse Cardiovascular Events, Thrombosis (Including Fatal Events) and Malignancy
Affected Products
CIBINQO (abrocitinib), INREBIC (fedratinib), JAKAVI (ruxolitinib), OLUMIANT (baricitinib), RINVOQ (upadacitinib), XELJANZ/XELJANZ XR (tofacitinib)
Additional Source Details
| Field | Value |
|---|---|
| N I D | 72122 |
| U R L | https://recalls-rappels.canada.ca/en/alert-recall/janus-kinase-inhibitors-and-risk-major-adverse-cardiovascular-events-thrombosis |
| Issue | New safety information - Product safety |
| Title | Janus Kinase Inhibitors and the Risk of Major Adverse Cardiovascular Events, Thrombosis (Including Fatal Events) and Malignancy |
| Product | CIBINQO (abrocitinib), INREBIC (fedratinib), JAKAVI (ruxolitinib), OLUMIANT (baricitinib), RINVOQ (upadacitinib), XELJANZ/XELJANZ XR (tofacitinib) |
| Archived | 0 |
| Category | Drugs |
| Last updated | 2022-10-31 |
| Organization | Marketed health products |